Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
Year: 2015
Type: review
Source: Biochemical Pharmacology
Institution: Pfizer (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2194989239
